다중혈관 관상동맥 환자에서 y-문합을 이용하여 양쪽 내흉동맥만을 사용한 우회술의 조기 성적

抗原变异可使得多种致病微生物易于逃避宿主免疫应答。表达在感染红细胞表面的恶性疟原虫红细胞表面蛋白1（PfPMP1）与感染红细胞、内皮细胞、树突状细胞以及胎盘的单个或多个受体作用，在黏附及免疫逃避中起关键的作用。每个单倍体基因组var基因家族编码约60种成员，通过启动转录不同的var基因变异体为抗原变异提供了分子基础。

疟原虫var基因转换速率变化导致抗原变异[英]／Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A

In recent years, the olefin metathesis reaction has attracted widespread attention as a versatile carbon−carbon bond-forming method. Many new applications have become possible because of major advances in catalyst design. State-of-the-art ruthenium catalysts are not only highly active but also compatible with most functional groups and easy to use. This Account traces the ideas and discoveries that were instrumental in the development of these catalysts, with particular emphasis on (PCy3)2Cl2RuCHPh and its derivatives. The discussion includes an analysis of trends in catalyst activity, a description of catalysts coordinated with N-heterocyclic carbene ligands, and an overview of ongoing work to improve the activity, stability, and selectivity of this family of L2X2RuCHR complexes.

http://web4.uwindsor.ca/users/j/jlichaa/reference.nsf/0/10ff8b04ff3a317885256d88005720f6/$FILE/acr-2001-34-18-metath-grubbs.pdf

The Development of L2X2RuCHR Olefin Metathesis Catalysts: An Organometallic Success Story

Controlled/living radical polymerization: Features, developments, and perspectives

N-Heterocyclic Carbenes in Late Transition Metal Catalysis

FDA-approved poly(ethylene glycol)–protein conjugate drugs

Protein–polymer conjugates are widely used as therapeutics. All Food and Drug Administration (FDA)-approved protein conjugates are covalently linked to poly(ethylene glycol) (PEG). These PEGylated drugs have longer half-lives in the bloodstream, leading to less frequent dosing, which is a significant advantage for patients. However, there are some potential drawbacks to PEG that are driving the development of alternatives. Polymers that display enhanced pharmacokinetic properties along with additional advantages such as improved stability or degradability will be important to advance the field of protein therapeutics. This perspective presents a summary of protein–PEG conjugates for therapeutic use and alternative technologies in various stages of development as well as suggestions for future directions. Established methods of producing protein–PEG conjugates and new approaches utilizing controlled radical polymerization are also covered.

Therapeutic protein-polymer conjugates: advancing beyond PEGylation.

Protein−polymer conjugates are widely used in biotechnology and medicine, and new methods to prepare the bioconjugates would be advantageous for these applications In this report, we demonstrate that bioactive “smart” polymer conjugates can be synthesized by polymerizing from defined initiation sites on proteins, thus preparing the polymer conjugates in situ In particular, free cysteines, Cys-34 of bovine serum albumin (BSA) and Cys-131 of T4 lysozyme V131C, were modified with initiators for atom transfer radical polymerization (ATRP) either through a reversible disulfide linkage or irreversible bond by reaction with pyridyl disulfide- and maleimide-functionalized initiators, respectively Initiator conjugation was verified by electrospray-ionization mass spectroscopy (ESI-MS), and the location of the modification was confirmed by μLC-MSMS (tandem mass spectrometry) analysis of the trypsin-digested protein macroinitiators Polymerization of N-isopropylacrylamide (NIPAAm) from the protein macroinitiators

In situ preparation of protein-"smart" polymer conjugates with retention of bioactivity.

The Lewis acid–base adduct approach has been widely used to form uniform perovskite films, which has provided a methodological base for the development of high-performance perovskite solar cells. However, its incompatibility with formamidinium (FA)-based perovskites has impeded further enhancement of photovoltaic performance and stability. Here, we report an efficient and reproducible method to fabricate highly uniform FAPbI3 films via the adduct approach. Replacement of the typical Lewis base dimethyl sulfoxide (DMSO) with N-methyl-2-pyrrolidone (NMP) enabled the formation of a stable intermediate adduct phase, which can be converted into a uniform and pinhole-free FAPbI3 film. Infrared and computational analyses revealed a stronger interaction between NMP with the FA cation than DMSO, which facilitates the formation of a stable FAI·PbI2·NMP adduct. On the basis of the molecular interactions with different Lewis bases, we proposed criteria for selecting the Lewis bases. Owed to the high film quality, per...

Tuning Molecular Interactions for Highly Reproducible and Efficient Formamidinium Perovskite Solar Cells via Adduct Approach

This communication reports the first example of polymerization initiated from specific domains on proteins. Streptavidin was coupled with a biotinylated initiator for atom transfer radical polymerization (ATRP) and exposed to an aqueous solution of CuBr/2,2‘-bipyridine and monomer. N-Isopropylacrylamide (NIPAAm) and poly(ethylene glycol) methyl ether methacrylate (PEGMA) were readily initiated by the modified streptavidin and polymerized from the protein at room temperature. Formation of streptavidin−polymer conjugates was confirmed by size exclusion chromatography (SEC) and gel electrophoresis. Polymer identity and biotinylation was verified using 1H NMR spectroscopy, gel permeation chromatography (GPC), and surface plasmon resonance (SPR) after dissociation of the biotin−streptavidin complex. This general approach is likely to be extended to other proteins and monomers and promises to enable easy synthesis and purification of a variety of polymer−protein conjugates.

Heather D. Maynard

Papers

FDA-approved poly(ethylene glycol)–protein conjugate drugs

Therapeutic protein-polymer conjugates: advancing beyond PEGylation.

In situ preparation of protein-"smart" polymer conjugates with retention of bioactivity.

Tuning Molecular Interactions for Highly Reproducible and Efficient Formamidinium Perovskite Solar Cells via Adduct Approach

Streptavidin as a macroinitiator for polymerization: in situ protein-polymer conjugate formation.